How Has the Guillain-Barre Syndrome Drugs Market Evolved Historically and What is its Current Size?
The guillain-barre syndrome drugs market has seen considerable growth due to a variety of factors.
• The guillain-barre syndrome drugs market has seen strong growth in recent years. It is projected to rise from $1.17 billion in 2024 to $1.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.2%.
This growth is driven by advancements in research and development, government support and regulatory assistance, increased focus on neurology and autoimmune diseases, efforts to reduce healthcare costs, and greater demand for hospital services.
What is the Forecasted Market Size and CAGR for the Guillain-Barre Syndrome Drugs Market?
The guillain-barre syndrome drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The Guillain-Barre Syndrome (GBS) drugs market is set for strong growth, reaching $1.71 billion by 2029 at a CAGR of 7.9%.
This growth is attributed to the rising GBS incidence, increasing recognition, aging population, and the role of hospital and retail pharmacies. Trends will include new therapies, advances in diagnostics, gene therapy development, and advancements in immunoglobulin treatments.
What Key Factors and Trends Are Driving The Growth Guillain-Barre Syndrome Drugs Market?
The rising demand for personalized medicine is expected to fuel the growth of the Guillain-Barre syndrome (GBS) drugs market. Personalized medicine tailors treatments to individual characteristics such as genetics or lifestyle to enhance efficacy and reduce side effects. Personalized treatments for GBS focus on improving therapeutic outcomes based on patient profiles. For example, in February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies in 2023, compared to just six in 2022. As a result, the increasing demand for personalized medicine will drive growth in the GBS drugs market.
What Are The Market Segments In The Guillain-Barre Syndrome Drugs Market?
The guillain-barre syndrome drugs market covered in this report is segmented –
1) By Drug Class: Immunoglobulins (IVIG), Corticosteroids, Plasma Exchange
2) By Treatment Type: First-Line Treatment, Adjunctive Or Supportive Treatment
3) By Application: Clinic, Hospital, Other Applications
Subsegments:
1) By Immunoglobulins (Ivig): Intravenous Immunoglobulin (Ivig) Therapy, Human Normal Immunoglobulin (Hnig), Hyperimmune Immunoglobulin Products, Ivig Formulations For Gbs Treatment, Monoclonal Antibodies As Part Of Ivig Treatment
2) By Corticosteroids: Methylprednisolone, Prednisolone, Dexamethasone, Hydrocortisone, Betamethasone, Oral Corticosteroid Formulations
3) By Plasma Exchange: Therapeutic Plasma Exchange (Tpe), Plasmapheresis Equipment For Gbs Treatment, Centrifugal Plasma Exchange, Immunoadsorption Plasma Exchange, Autologous Plasma Exchange (Ape)
Pre-Book The Guillain-Barre Syndrome Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Guillain-Barre Syndrome Drugs Market?
Leading corporations in the guillain-barre syndrome drugs market, such as Annexon Inc., are pioneering new products, like humanized monoclonal antibodies, to maintain their market standing. This kind of antibody is a hybrid of a human antibody and a small fragment of a mouse or rat monoclonal antibody - produced in a laboratory and seen as potential treatments due to their specificity in targeting immune system aspects linked to guillain-barre syndrome (GBS). In October 2023, Annexon Inc., a clinical-stage biopharmaceutical company based in the U.S., received orphan drug designation from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for their novel GBS treatment, ANX005. This humanized monoclonal antibody, ANX005, curbs C1q to prevent inflammation and early neuropathic damage in guillain-barre patients. Annexon has successfully enrolled the target number of participants in Phase 3 trials of ANX005 in GBS patients, with primary data anticipated in the initial half of 2024. By selectively blocking C1q activity in the nervous system, ANX005 aims to attenuate inflammation and nerve harm, thereby speeding up the halt of autoimmune damage and reviving muscle strength in GBS patients.
Who Are the Key Players In The Guillain-Barre Syndrome Drugs Market?
Major companies operating in the guillain-barre syndrome drugs market are:
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• Grifols SA
• Octapharma AG
• Cadila Healthcare Limited
• Argenx SE
• Alnylam Pharmaceuticals Inc.
• Biotest AG
• CSL Behring LLC
• Kedrion Biopharma Inc.
• Cellenkos Inc.
• Annexon Inc.
• Hansa Medical AB
• Akari Therapeutics Plc
• Alexion Pharmaceuticals Inc.
• Vitality Biopharma Inc.
• CuraVac Inc.
• Regenesance BV
• Cresence AS
• Shire Plc
What Are The Regional Insights Into The Guillain-Barre Syndrome Drugs Market?
North America was the largest region in the guillain-barre syndrome drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the guillain-barre syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
